Medical device&diagnostic executive

Sales and Market Excellence 2010 Europe

17-18 March 2010 | Regent's Park Marriott, London

Grow and retain talent, respond to the changing healthcare environment and sustain high growth
Imagine if you could convert change into opportunity and deliver dramatically increased sales.

New Multi-Marketing Channel Strategies

The future of Pharma marketing lies in using new marketing channels such as social media intertwined with traditional marketing practices to create a multi-channel marketing mix. However, online brand promotion through social media is more effective for targeting patients than physicians, indicating direct marketing tactics to physicians through social media should be limited.

Generic Strategies in Emerging Markets

The emerging markets are luring a growing number of pharma companies looking to compensate for the diminishing revenues in developed markets. Latin America and Central and Eastern Europe (CEE) are showing strong growth rates, proving to be lucrative targets for firms aiming to expand their foothold, initially as a generics player, but also providing a foundation for subsequent brand penetration.

Mapping the Healthcare Landscape: Bringing pharmaceuticals into focus

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Big Pharma seeks to insulate itself from impact of patent cliff

The pharmaceutical industry is facing an impending patent cliff, when some of its biggest selling drugs will lose patent protection and become exposed to generic competition. While companies are seemingly investing as much into diversification as they are into R&D, a new Datamonitor report suggests that moving away from the core business of prescription drugs may not be the best strategy.

PHYSICOCHEMICAL EVALUATION AND ETHNOMEDICINAL USES OF MICHELIA CHAMPACA LINN.

Michelia champaca L. is a medicinal and ornamental plant cultivated in home gardens and near temples for its scented, attractive and massive pale colored flowers. Beside, being an ornamental plant, its various parts are medicinally used in the treatment of different human ailments. The present work was done to evaluate the physicochemical parameters viz., total ash, acid insoluble ash, water soluble ash, moisture content and FOM of leaves of the plant and to enumerate the ethnomedicinal uses of the herb.

The whole 6 pages article is available for download at Downloads section of Farmavita.Net.

Pharma's fourth hurdle - market access

LONDON (November 04, 2009) - Getting regulatory agency approval for a new drug was once the end goal of pharmaceutical drug development, but in today's healthcare environment where governments increasingly determine price and the availability of drugs to patients through formulary designation, market access has become the "fourth hurdle" in successfully bringing a drug to market.

8th annual SFE Europe 2010

Barcelona, April 27-29th 2010

Historically in pharma, change is something we react to. It's not something we want, or choose. We try to figure out how to blow the competition out of the water, in ‘5 easy steps', but if it means inherently changing then forget it. Maybe now is the time to stop thinking this way. Maybe now is the time that we can change, try it out, find our feet, and innovate. Change, in case you hadn't noticed, is what SFE Europe is all about for 2010.

Challenges in standardization in Traditional Medicine / Herbal Drugs

The use of herbs and herbal extracts to treat diseases has stood the test of time. Herbal products/traditional medicine are composed of many constituents and are, therefore, capable of variation. The variability of the plant material is due to different conditions of growth, harvesting, drying, and storage. The polarity of the solvent, the mode of extraction, and the instability of constituents may also influence the composition and quality of the extracts.

The whole 10 pages article is available for download at Downloads section of Farmavita.Net.

Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan

Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. However, facing increasingly saturated markets in the West, companies are looking to expand into new geographies, such as Asia's emerging markets.

Influenza Vaccines and Antivirals - The pandemic's long-term impact

Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but also confronts industry and public health stakeholders with new challenges.

H1N1 influenza pandemic: public apathy threatens infection control

Following initial heightened fears, the public's attitude towards the H1N1 virus has changed, with many people now skeptical over the potential health threat. However, the virus is expected to continue to spread and stabilizing supply, along with educating the public about the medical and societal need for vaccination will be crucial for the success of H1N1 infection control.

COMPARATIVE EVALUATION STUDY OF INSECTICIDAL PLANTS FOR THE CONTROL OF VECTOR MOSQUITO ANOPHELES STEPHENSI

Aim of this work was to comparative study on larvicidal activity of insecticidal plants against malaria spreading mosquito Anopheles stephensi. The petroleum ether and chloroform extracts of Lantana camara showed highest larvicidal activity against the mosquito vector Anopheles stephensi in comparison to Toddalia asiatica.

The whole 15 pages article is available for download at Downloads section of Farmavita.Net.

The Diabetes Market Outlook to 2011

The Diabetes Market Outlook to 2011 provides in-depth insights into new product launches, upcoming patent expiries and on-going clinical trials in order to predict changes in global market dynamics. Key R&D trends are analyzed and pipeline compounds of the top players are evaluated, enabling you to strengthen your position in the diabetes market and anticipate future product success.

EASD 2009: Lantus defended amid allegations of increased cancer risk

Datamonitor attended this year's European Association for the Study of Diabetes meeting in Vienna, Austria. Following the issuance of guidance on a potential link between Lantus and increased cancer rates in June 2009, presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed.

Eudragit and its Pharmaceutical Significance

One would always like to have an ideal drug delivery system that will possess three main properties: (a) It will be a single dose for the whole duration of treatment. (b) It will deliver the active drug directly at the site of action. (c) It will possess possible fewer side effects. Above approaches are achieved with the help of suitable choice of polymer.

The whole 17 pages article is available for download at Downloads section of Farmavita.Net.

RECENT ADVANCES IN CARBON NANOTUBES A PROMISING APPROACHES IN CANCER THERAPY

The carbon nanotube's structure can be thought of as a sheet of graphite which has been rolled into a cylinder. A nanotube can also contain multiple cylinders of different diameters nested inside one another. This type is called a multi-wall nanotube (MWNT).

The whole 28 pages article is available for download at Downloads section of Farmavita.Net.

Molecular Targeted Cancer Therapies - Leading companies will hold onto competitive advantage in high growth market

Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market.